Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection

Simple item page
dc.contributor.authorMondal, Shakhinur Islamen
dc.contributor.authorDraper, Lorraine A.en
dc.contributor.authorRoss, R. Paulen
dc.contributor.authorHill, Colinen
dc.contributor.funderHorizon 2020en
dc.date.accessioned2023-05-31T08:55:40Z
dc.date.available2023-05-31T08:55:40Z
dc.date.issued2020-09-28en
dc.description.abstractClostridioides difficile is the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment of C. difficile infections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages of C. difficile and their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues of C. difficile endolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleide1813533en
dc.identifier.citationMondal, S. I., Draper, L. A., Ross, R. P. and Hill, C. (2020) 'Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection', Gut Microbes, 12(1), e1813533 (15pp). doi: 10.1080/19490976.2020.1813533en
dc.identifier.doi10.1080/19490976.2020.1813533en
dc.identifier.eissn1949-0984en
dc.identifier.endpage15en
dc.identifier.issn1949-0976en
dc.identifier.issued1en
dc.identifier.journaltitleGut Microbesen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/14525
dc.identifier.volume12en
dc.language.isoenen
dc.publisherTaylor & Francis Groupen
dc.relation.projectinfo:eu-repo/grantAgreement/EC/H2020::MSCA-COFUND-FP/754535/EU/APC Postdoctoral EXcellence Programme/APEXen
dc.rights© 2020, the Authors. Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectClostridioides difficileen
dc.subjectEndolysinen
dc.subjectBacteriophageen
dc.subjectAntimicrobialsen
dc.subjectClostridioides difficile infectionsen
dc.subjectAntibioticsen
dc.subjectNovel therapyen
dc.titleBacteriophage endolysins as a potential weapon to combat Clostridioides difficile infectionen
dc.typeArticle (peer-reviewed)en
oaire.citation.issue1en
oaire.citation.volume12en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection.pdf
Size:
2.57 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles
Microbiology - Journal Articles